RxDoctor Payments Data

Shane Tipton, PA

Physician Assistant · Stanford, CANPI 1962482877

Payments from drug & device makers

$512in general payments, 2019–2025

Across 19 payments — averaging $26.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tempus AI, Inc$238
  • Myriad Genetic Laboratories, Inc.$50
  • Pfizer$44
  • Eisai Inc.$44
  • Acrotech Biopharma Inc.$40
  • Novartis$32
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$38475%
  • Education$12725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$512 in reported general payments places this provider in the 60th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$133,654
Medicare patients
685
Services billed
1,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide24$407,919
ImbruvicaIbrutinib33$334,464
XtandiEnzalutamide21$283,073
InlytaAxitinib13$255,518
VenclextaVenetoclax35$86,118
Abiraterone Acetate108$42,808
EliquisApixaban41$31,721
Imatinib Mesylate20$11,512
Xtampza ErOxycodone Myristate13$7,018
Fentanyl30$3,091
Anastrozole105$2,626
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen35$2,082
Exemestane24$1,664
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen48$1,470
Ondansetron Hcl86$1,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta, Eliquis$44$287,23954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →